What top creators are saying about CorMedix Inc.(CRMD)

Mentioned as an example of a stock whose value dropped due to a draft report from CMS suggesting unfavorable reimbursement, reinforcing the theme of CMS risk for companies in the 'sickcare' system.

Presents a high-risk, high-reward value play after a significant price drop. The stock is considered 'dirt cheap' but faces major uncertainty due to a crucial pricing renegotiation with CMS for its main product in 2026.

Presented as a very bullish opportunity due to its 'super special' cheap valuation combined with outstanding financial metrics: 120% projected revenue growth, 41% EBITDA margin, and a Rule of 40 score of 161.

The company is considered 'dirt cheap' with a P/E of 5.66, despite having 120% forward revenue growth and high profitability, suggesting the market is misclassifying it as a risky pre-revenue biotech.

Bullish view based on the company being a deep value opportunity, calling it 'way too cheap' due to its extremely low valuation (EV/GP/RG of 0.029) and high gross margins (96%).

Used as an example of a company with 'outstanding earnings' that still experienced a stock price drop, indicating that the market is driven by Fed policy rather than fundamentals.

Had an 'outstanding, outstanding Q3' and its sell-off is considered irrational as its business is non-cyclical and reimbursed by Medicare, suggesting a significant disconnect from fundamentals.

The company is fundamentally strong, fast-growing, and profitable, but believed to be trading at a very low valuation ('dirt cheap') and is 'unfairly punished' by broader market sentiment against growth stocks.

Holds a very bullish view, stating the stock 'had no business getting below $10' and remains 'extremely cheap' even after a 17% jump driven by high revenue and an analyst upgrade. Growth is 'predicted to go 200%'.

Called 'dirt cheap' and a significant buying opportunity due to its low valuation despite strong fundamentals, including projected revenue growth of 180% and a 96% gross margin.

Described as 'dirt cheap' (EV/GP/RG of 0.04) with high-upside potential as it begins its commercial rollout. The company has a strong value proposition, saving the healthcare system significant costs.

Considered a deep value play that is 'so, so, so cheap'. Its unique FDA-approved product saves the healthcare system money, and a recent acquisition of Melinta de-risks the company's single-product status.

Cited as a more compelling alternative to SMTI, with much higher predicted growth (120%-180%) and appearing cheaper on the host's key valuation metric (EV/GP/RG of 0.03-0.04).

The stock is described as 'dirt cheap' and the recent acquisition of Melinta Therapeutics is viewed as a 'really, really good' move that transforms it into a multi-product company with significantly higher revenue potential, despite the market's negative reaction.

The speaker is bullish on the company's strong fundamentals (180% growth rate) and views the recent 30% price drop, caused by a confusingly timed stock offering, as a buying opportunity disconnected from excellent business performance.

The speaker is very bullish, viewing a recent stock drop from a public offering as a buying opportunity. Expects revenue to 'explode' as its product, DefenCath, becomes the standard of care in dialysis.